JUL
02

APPROVAL FOR MARKETING OF THE GROUP'S PRODUCT TADALAFIL TABLETS

JUN
30

List of Directors and Their Role and Function

JUN
30

RETIREMENT OF EXECUTIVE DIRECTOR

JUN
30

Final dividend for the year ended 31 December 2025

JUN
29

PAYMENT OF 2025 FINAL DIVIDEND

JUN
23

POLL RESULTS OF THE 2026 ANNUAL GENERAL MEETING

JUN
11

APPROVAL FOR CLINICAL TRIAL OF THE GROUP'S PRODUCT TUL321 CAPSULES

JUN
11

VOLUNTARY ANNOUNCEMENT PROPOSED SHARE BUY-BACK UNDER GENERAL MANDATE

MAY
19

APPROVAL FOR CLINICAL TRIAL OF GROUP'S PRODUCT TUL108 FOR INJECTION

MAY
15

List of Directors and Their Role and Function

MAY
15

RESIGNATION OF EXECUTIVE DIRECTOR

MAY
07

APPROVAL FOR CLINICAL TRIAL OF GROUP'S PRODUCT UBT38006 INJECTION

APR
29

NOTICE OF ANNUAL GENERAL MEETING

APR
28

FDA APPROVAL OF IND FOR GROUP'S PRODUCT TUL321 CAPSULES

APR
22

APPROVAL FOR CLINICAL TRIAL OF THE GROUP'S PRODUCT DUPILUMAB INJECTION

MAR
31

CLARIFICATION ANNOUNCEMENT TO 2025 ANNUAL RESULTS ANNOUNCEMENT

MAR
26

Final dividend for the year ended 31 December 2025

MAR
25

PROGRESS IN CLINICAL TRIAL OF THE GROUP'S PRODUCT UBT251 INJECTION

MAR
24

2025 ANNUAL RESULTS ANNOUNCEMENT

MAR
12

PROFIT WARNING

MAR
09

APPROVAL FOR MARKETING OF THE GROUP'S PRODUCT INSULIN DEGLUDEC INJECTION

MAR
09

DATE OF BOARD MEETING

FEB
24

PROGRESS IN CLINICAL TRIAL OF THE GROUP'S PRODUCT UBT251 INJECTION

FEB
09

THE GROUP'S PRODUCT ROXITHROMYCIN CAPSULES PASSED THE CONSISTENCY EVALUATION

FEB
03

APPROVAL FOR CLINICAL TRIAL OF UBT251 INJECTION ON INDICATION OF OSA

JAN
28

FDA APPROVAL OF IND FOR GROUP'S PRODUCT TUL108 FOR INJECTION